HeLa cells up-regulate Beclin1/autophagy pathway to confer resistance to doxorubicin

您当前的位置：

首页 >

文章列表页 >

HeLa cells up-regulate Beclin1/autophagy pathway to confer resistance to doxorubicin

Basic Medicine | 更新时间：2026-01-09

- HeLa cells up-regulate Beclin1/autophagy pathway to confer resistance to doxorubicin
- Journal of Third Military Medical University Vol. 41, Issue 13, Pages: 1216-1221(2019)
- 作者机构：
  
  1.100049 北京，航天中心医院妇产科
  2.100048 北京，解放军总医院第六医学中心
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.201903084
  CLC： R737.33;R966;R979.14
- Received：10 March 2019，
  
  Revised：2019-05-01，
  
  Published：15 July 2019
- 稿件说明：
移动端阅览
Yanjun GUO, Shuwei WANG. HeLa cells up-regulate Beclin1/autophagy pathway to confer resistance to doxorubicin[J]. Journal of Third Military Medical University, 2019, 41(13): 1216-1221.
DOI：

Yanjun GUO, Shuwei WANG. HeLa cells up-regulate Beclin1/autophagy pathway to confer resistance to doxorubicin[J]. Journal of Third Military Medical University, 2019, 41(13): 1216-1221. DOI： 10.16016/j.1000-5404.201903084.

摘要

目的

2

观察多柔比星(doxorubicin

DOX)在HeLa细胞中诱导保护性自噬反应的作用，探讨HeLa细胞对DOX治疗抵抗的可能机制。

方法

2

用不同剂量(0、2、4、8、16 mg/L)多柔比星处理人宫颈癌HeLa细胞，CCK-8法检测细胞活力，定量PCR检测DOX处理对自噬相关基因mRNA的影响，Western blot分析DOX处理对自噬相关蛋白表达的影响，用siRNA沉默Beclin1，CCK-8法检测DOX对HeLa细胞活力的影响，把含有Beclin1启动子片段的报告质粒转入HeLa细胞，通过报告基因系统检测DOX处理对Beclin1启动子活性的影响，用转录抑制剂放线菌素D预处理HeLa细胞，然后用定量PCR分析DOX处理不同时间对Beclin1 mRNA稳定性的影响。

结果

2

DOX可剂量依赖性抑制HeLa细胞活力，并诱导细胞的保护性自噬反应，抑制自噬可增强HeLa细胞对DOX的敏感性。DOX可特异性地升高HeLa细胞中Beclin1的mRNA和蛋白水平(

P

<

0.05)。沉默Beclin1可增强DOX对HeLa细胞的杀伤效果。DOX处理不影响HeLa细胞中Beclin1的启动子活性(

P

>

0.05)，但显著增强其mRNA的稳定性(

P

<

0.05)。

结论

2

DOX可能通过增强Beclin1/自噬通路而导致HeLa细胞对其耐受。

Abstract

Objective

2

To investigate the role of doxorubicin (DOX) in the induction of protective autophagy in HeLa cells and explore the possible mechanism of DOX resistance.

Methods

2

HeLa cells were treated with DOX at different doses (0

2

4

8 and 16 mg/L) for 24 h

and the cell viability was measured by CCK-8 assay. The mRNA levels of autophagy-related genes were assessed using qRT-PCR

and the protein levels were detected by Western blotting. After Beclin1 was knockdowned through siRNA

the effect of DOX on cell viability was detected by CCK-8 assay. The effect of DOX on the promoter activity of Beclin1 in HeLa cells was assessed using the reporter gene assay after transfection with a plasmid containing Beclin1 promoter. The stability of Beclin1 mRNA was analyzed with qPCR in HeLa cells after treatment with DOX alone or DOX combined with the transcription inhibitor actinomycin D.

Results

2

DOX inhibited the cell viability in HeLa cells in a dose-dependent manner. DOX also induced protective autophagy in HeLa cells. Inhibition of autophagy enhanced the sensitivity of HeLa cells to DOX. DOX treatment resulted in special up-regulation of Beclin1 at both mRNA and protein levels in HeLa ce

lls (

P

<

0.05). Knockdown of Beclin1 significantly increased DOX-triggered proliferation suppression in HeLa cells. DOX treatment did not significantly affect the promoter activity of Beclin1

but obviously lowered the mRNA stability of Beclin1 in HeLa cells.

Conclusion

2

DOX may induce drug resistance in HeLa cells through enhancing the Beclin1/autophagy pathway.

关键词

Keywords

references

BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI:10.3322/caac.21492.

COHEN P A, JHINGRAN A, OAKNIN A, et al . Cervical cancer[J ] . Lancet, 2019, 393(10167): 169-182. DOI:10.1016/S0140-6736(18)32470-X.

RIVANKAR S. An overview of doxorubicin formulations in cancer therapy[J]. J Cancer Res Ther, 2014, 10(4): 853-858. DOI:10.4103/0973-1482.139267.

MOHAJERI M, SAHEBKAR A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review[J]. Crit Rev Oncol Hematol, 2018, 122: 30-51. DOI:10.1016/j.critrevonc.2017.12.005.

SAHA S, PANIGRAHI D P, PATIL S, et al . Autophagy in health and disease: A comprehensive review[J ] . Biomed Pharmacother, 2018, 104: 485-495. DOI:10.1016/j.biopha.2018.05.007.

PRIETO-DOMÍNGUEZ N, GARCIA-MEDIAVILLA M V, SANCHEZ-CAMPOS S, et al . Autophagy as a molecular target of flavonoids underlying their protective effects in human disease[J ] . Curr Med Chem, 2018, 25(7): 814-838. DOI:10.2174/0929867324666170918125155.

TAYLOR M A, DAS B C, RAY S K. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma[J]. Apoptosis, 2018, 23(11/12): 563-575. DOI:10.1007/s10495-018-1480-9.

YUNIARTI L, MUSTOFA M, ARYANDONO T, et al . Synergistic action of 1, 2-epoxy-3 (3- (3, 4-dimethoxyphenyl)- 4H-1-benzopiyran-4-on) propane with doxorubicin and cisplatin through increasing of p53, TIMP-3, and microRNA-34a in cervical cancer cell line (HeLa)[J ] . Asian Pac J Cancer Prev, 2018, 19(10): 2955-2962. DOI:10.22034/APJCP.2018.19.10.2955.

XIA Y, XU T, ZHAO M, et al . Delivery of doxorubicin for human cervical carcinoma targeting therapy by folic acid-modified selenium nanoparticles[J ] . Int J Mol Sci, 2018, 19(11): E3582. DOI:10.3390/ijms19113582.

QIU F, ZHAO X. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations[J]. J BUON, 2018, 23(1): 117-123.

MUTLU P, YALÇIN AZARKAN S, TAGHAVI POURIANAZAR N, et al . Determination of the relationship between doxorubicin resistance and Wnt signaling pathway in HeLa and K562 cell lines[J ] . EXCLI J, 2018, 17: 386-398. DOI:10.17179/excli2018-1129.

WAGNER W, KANIA K D, BLAUZ A, et al . The lactate receptor (HCAR1/GPR81) contributes to doxorubicin chemoresistance via ABCB1 transporter up-regulation in human cervical cancer HeLa cells[J ] . J Physiol Pharmacol, 2017, 68(4): 555-564..

XU J, PAN Q, JU W.Ras inhibition by zoledronic acid effectively sensitizes cervical cancer to chemotherapy[J].Anticancer Drugs, 2019..DOI: 10.1097/CAD.0000000000000779.

GUAN S, LU J X, ZHAO Y L, et al . TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis[J ] . Oncotarget, 2017, 8(20): 33666-33675. DOI:10.18632/oncotarget.16895.

GUO K Y, HAN L L, LI X Y, et al . Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway[J ] . Oncotarget, 2017, 8(69): 114123-114135. DOI:10.18632/oncotarget.23166..

DAGLIOGLU C, KACI F N. Cascade therapy with doxorubicin and survivin-targeted tailored nanoparticles: An effective alternative for sensitization of cancer cells to chemotherapy[J]. Int J Pharm, 2019, 561: 74-81. DOI:10.1016/j.ijpharm.2019.02.036.

WU Y R, NI Z H, YAN X J, et al . Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin[J ] . Autophagy, 2016, 12(7): 1105-1117. DOI:10.1080/15548627.2016.1173798.

XIONG H, NI Z, HE J, et al . LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells[J ] . Oncogene, 2017, 36(25): 3528-3540. D OI:10.1038/onc.2016.521..

KRANZBÜHLER B, SALEMI S, MORTEZAVI A, et al . Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells[J ] . Prostate, 2019, 79(2):206-214. DOI: 10.1002/pros.23725.

SUN W L, WANG L, LUO J, et al . Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12[J ] . Cancer Sci, 2018, 109(10): 3129-3138. DOI:10.1111/cas.13743.

ZHANG N, WU Y R, LYU X L, et al . HSF1 upregulates ATG4B expression and enhances epirubicin-induced protective autophagy in hepatocellular carcinoma cells[J ] . Cancer Lett, 2017, 409: 81-90. DOI:10.1016/j.canlet.2017.08.039.

CHEN C, LU L, YAN S C, et al . Autophagy and doxorubicin resistance in cancer[J ] . Anticancer Drugs, 2018, 29(1): 1-9. DOI:10.1097/CAD.0000000000000572.

FERNANDES Â, AZEVEDO M M, PEREIRA O, et al . Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches[J ] . Onc otarget, 2015, 6(31): 31428-31440. DOI:10.18632/oncotarget.2947.

DI FAZIO P, MATROOD S. Targeting autophagy in liver cancer[J]. Transl Gastroenterol Hepatol, 2018, 3: 39. DOI:10.21037/tgh.2018.06.09.

WU C L, LIU J F, LIU Y, et al . Beclin1 inhibition enhances paclitaxel-mediated cytotoxicity in breast cancer in vitro and in vivo [J ] . Int J Mol Med, 2019, 43(4): 1866-1878. DOI:10.3892/ijmm.2019.4089..

GANDHI M, CAUDRON-HERGER M, DIEDERICHS S. RNA motifs and combinatorial prediction of interactions, stability and localization of noncoding RNAs[J]. Nat Struct Mol Biol, 2018, 25(12): 1070-1076. DOI:10.1038/s41594-018-0155-0.

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Related Articles

RANKL通过ROS介导HIF-1α下调促进自噬和破骨细胞分化

转录因子EB增强巨噬细胞自噬功能及逆转内毒素耐受的作用

Autophagy inducer spermidine improves brain injury after intracerebral hemorrhage

AKT1-mediated autophagy of hepatocellular carcinoma cells enhances cell sensitivity to ¹²⁵I seed irradiation

Effect of overexpression of TPX2 gene on apoptosis and invasion in human cervical cancer HeLa cells

Related Author

LI Songtao

SUN Jing

CHU Tongwei

YANG Ting

LIU Xin

JIANG Qingsong

WANG Yujie

SHI Xinhui

Related Institution

Department of Cerebrovascular Diseases， Second Affiliated Hospital of Zhengzhou University, Zhengzhou University

Academy of Medical Sciences, Zhengzhou University

Department of Nuclear Medicine， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Obstetrics and Gynecology, the Affiliated Hospital of Inner Mongolia Medical College, Hohhot, Inner Mongolia Autonomous Region

⁰